Genomic Vision

First-Half 2023 Results

Regulatory News:

Genomic Vision (FR0011799907 – GV, – the “Company”), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces its half-year financial results for the six months ended 30^th June 2023¹. The first-half financial report 2023 is available on Genomic Vision's website in the Investors section.

H1 2023 results

(in € thousands - IFRS)	6/30/2023	6/30/2022
Sales	593	511
Other revenue	233	232
Total revenue from activity	826	743
Current operating expenses	- 5,956	- 3,197
Current operating loss	- 5,130	- 2,454
Other operating expenses/income		- 57
Operating loss	- 5,130	- 2,510
Cost of financial debt and other financial expenses/income	- 1,269	- 58
Net loss	- 6,400	- 2,568

Revenue from sales totaled €593 thousand, growing by 16% compared to the same period last year. During each of these initial half-year periods, a platform was sold: one to the University of Florida in 2022 and another to the Institute of Cancer Research (ICR), London in the current half-year. Over the course of the period, the Company has continued consolidating its offerings while enhancing efficiency in production logistics and customer relationship management.

Taking into account other revenue, the total revenue from activity increased by 11%, amounting to €826 thousand, compared to the same period last year. Other income, amounting to €233 thousand on 30^th June 2023, corresponded to the Research Tax Credit.

Current operating expenses rose by 86% to €6 million, breaking down as follows in addition to cost of sales:

• R&D costs of €3.1 million, compared with €1.6 million in the first half of 2022, an increase of 97%. This increase reflects the Company's intensified focus on high-value projects, especially within Cell and Gene Therapy and Bioproduction sectors. A prime example is the collaboration with Cambridge Consultants to develop a cutting-edge micro-fluidics technology platform.
• Sales and marketing expenses amounted to €0.45 million, marking a 70% rise from the figure as of 30^th June 2022. This increase stems from staff reorganization within the department, a pronounced attendance at scientific and trade exhibitions, and a comprehensive revamp of digital communications.
• €1.4 million in overheads, down by €56 thousand compared with the first half of 2022.

Operating loss was €5.1 million at 30^th June 2023, compared with €2.5 million at 30^th June 2022. Net loss at 30^th June 2023 was €6.4 million, compared with €2.5 million for the six months to 30^th June 2022.